Who has invested in Oculis?

Alerce Medical Technology Partners are named among the investors backing Oculis.

Oculis Funding: $250M Raised, IPO (2023)

Oculis funding overview

Oculis is a Biotech company based in Lausanne, Switzerland. Oculis has raised $250M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is an IPO announced in January 2023. The round record for Oculis runs through 2023; nothing later has been disclosed. Investors on record include Alerce Medical Technology Partners.

Oculis at a glance

Total raised: $250M
Latest round: IPO
Latest round date: January 2023
Industry: Biotech
Headquarters: Lausanne, Switzerland
Notable investors: Alerce Medical Technology Partners

Frequently asked about Oculis funding

How much has Oculis raised?: Oculis has raised $250M in total disclosed funding across the rounds on record.
Who has invested in Oculis?: Alerce Medical Technology Partners are named among the investors backing Oculis.
What was the latest Oculis funding round?: The most recent disclosed round is an IPO, announced in January 2023.
Where is Oculis based?: Oculis is based in Lausanne, Switzerland.
What sector does Oculis operate in?: Oculis is tracked under Biotech from Lausanne, Switzerland, with $250M in disclosed funding.
When did Oculis last raise?: The last disclosed Oculis round closed in January 2023 at IPO.

Oculis totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related Biotech companies in Lausanne below to benchmark round size and investor mix.

Oculis Funding: $250M Raised, IPO (2023)

Oculis funding overview

Oculis at a glance

Frequently asked about Oculis funding

Oculis founders (1)

Companies related to Oculis (36)

Browse related funding lists (3)